Man Group’s Mersana Therapeutics MRSN Stock Holding History

Man Group’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,784	Closed	-$103K	–	2218
2023 Q4	$103K	Buy	+1,784	New	+$71.8K	﹤0.01%	1982
2023 Q1	–	Sell	-639	Closed	-$89.7K	–	1965
2022 Q4	$93.5K	Buy	+639	New	+$108K	﹤0.01%	1917
2022 Q2	–	Sell	-2,280	Closed	-$227K	–	2287
2022 Q1	$227K	Buy	+2,280	New	+$266K	﹤0.01%	1893

Other funds holding MRSN

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Man Group's MRSN Position: Q1 2024 in Review

Man Group sold out of Mersana Therapeutics (MRSN) in Q1 2024, closing a stake of 1,784 shares — an estimated $103K sold.

Man Group first reported a position in MRSN in Q1 2022 and held it in 3 quarters. The position peaked at $227K in Q1 2022. 122 funds tracked by Wall St. Rank hold MRSN as of Q1 2024.

Man Group reported no remaining Mersana Therapeutics position as of Q1 2024 after selling out during the quarter.
Man Group sold 1,784 Mersana Therapeutics shares in Q1 2024, an estimated $103K.
Man Group first reported a position in Mersana Therapeutics in Q1 2022 and held it in 3 quarters.
Man Group's Mersana Therapeutics position peaked at $227K in Q1 2022.
122 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2024.

Based on Man Group's 13F filing for Q1 2024, filed 15 May 2024.